MediWound to Report Second Quarter 2025 Financial Results
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, will release its Q2 2025 financial results on Thursday, August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide corporate updates.
Investors can access the call via multiple channels including toll-free numbers for US and Israel, and an international dial-in. A webcast replay will be available in the Investors section of MediWound's website after the call.
MediWound (Nasdaq: MDWD), leader nelle terapie enzimatiche per la riparazione dei tessuti, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 giovedì 14 agosto 2025. L'azienda terrà una conference call e una trasmissione in webcast alle 8:30 AM ora orientale per discutere i risultati e fornire aggiornamenti aziendali.
Gli investitori potranno partecipare alla chiamata tramite diversi canali, inclusi numeri verdi per USA e Israele, oltre a un numero internazionale. Una registrazione del webcast sarà disponibile nella sezione Investitori del sito web di MediWound dopo la chiamata.
MediWound (Nasdaq: MDWD), líder en terapias enzimáticas para la reparación de tejidos, publicará sus resultados financieros del segundo trimestre de 2025 el jueves 14 de agosto de 2025. La compañía realizará una conferencia telefónica y una transmisión por webcast a las 8:30 a.m. hora del este para discutir los resultados y brindar actualizaciones corporativas.
Los inversores podrán acceder a la llamada a través de múltiples canales, incluidos números gratuitos para EE. UU. e Israel, y una llamada internacional. Una repetición del webcast estará disponible en la sección de Inversores del sitio web de MediWound después de la llamada.
MediWound (나스닥: MDWD)는 조직 재생을 위한 효소 치료 분야의 선두주자로, 2025년 2분기 재무 결과를 2025년 8월 14일 목요일에 발표할 예정입니다. 회사는 결과를 논의하고 기업 업데이트를 제공하기 위해 동부 표준시 오전 8시 30분에 컨퍼런스 콜과 웹캐스트를 진행합니다.
투자자들은 미국과 이스라엘의 무료 전화번호 및 국제 전화번호를 포함한 여러 경로를 통해 콜에 참여할 수 있습니다. 콜 이후 MediWound 웹사이트의 투자자 섹션에서 웹캐스트 재방송을 시청할 수 있습니다.
MediWound (Nasdaq : MDWD), leader dans les thérapeutiques enzymatiques pour la réparation des tissus, publiera ses résultats financiers du deuxième trimestre 2025 le jeudi 14 août 2025. La société organisera une conférence téléphonique et une diffusion en webcast à 8h30, heure de l'Est pour discuter des résultats et fournir des mises à jour d'entreprise.
Les investisseurs pourront accéder à l'appel via plusieurs canaux, y compris des numéros sans frais pour les États-Unis et Israël, ainsi qu'un numéro d'appel international. Une rediffusion du webcast sera disponible dans la section Investisseurs du site web de MediWound après l'appel.
MediWound (Nasdaq: MDWD), ein führendes Unternehmen im Bereich enzymatischer Therapeutika zur Gewebereparatur, wird seine Finanzergebnisse für das zweite Quartal 2025 am Donnerstag, den 14. August 2025 veröffentlichen. Das Unternehmen wird um 8:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast veranstalten, um die Ergebnisse zu besprechen und Unternehmensupdates zu geben.
Investoren können über verschiedene Kanäle an dem Anruf teilnehmen, darunter gebührenfreie Nummern für die USA und Israel sowie eine internationale Einwahlnummer. Eine Aufzeichnung des Webcasts wird nach der Telefonkonferenz im Investor-Bereich der MediWound-Website verfügbar sein.
- None.
- None.
MediWound to Report Second Quarter 2025 Financial Results
Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time
YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025.
Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.
Dial-in and call details are as follows:
Conference Call & Webcast Details
Toll-Free: 1-844-676-8833
Israel: 1-80-9212373
International: 1-412-634-6869
Webcast: Webcast Link
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
For more information visit www.mediwound.com and follow us on LinkedIn.
MediWound Contacts:
Hani Luxenburg Daniel Ferry
Chief Financial Officer Managing Director
MediWound Ltd. LifeSci Advisors, LLC
ir@mediwound.com daniel@lifesciadvisors.com
Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
+1-929-588-2008
FAQ
When will MediWound (MDWD) report Q2 2025 earnings?
What time is MediWound's Q2 2025 earnings call?
How can I join MediWound's Q2 2025 earnings call?
Where can I find the replay of MediWound's Q2 2025 earnings call?
